Table 2. Detected microorganisms during different chemotherapy cycles.
| Total N = 589 (%) |
Induction N = 103 (%) |
Consolidation N = 176 (%) |
Neutropenia N = 376 |
|
|---|---|---|---|---|
| Gram negative-bacteria | 257 (43.6) | 39 (37.9) | 75 (42.6) | 82 (39) |
| E. coli | 120 (20.4) | 13 (12.6) | 40 (22.7) | 95 (25.3) |
| Ciprofloxacin R* | 99 (82.5) | 11 (84.6) | 37 (92.5) | 81 (85.3) |
| ESBL* | 31 (25.8) | 2 (15.4) | 9 (5.1) | 24 (25.2) |
| Klebsiella spp | 28 (4.8) | 5 (4.9) | 7 (4) | 15 (4) |
| Ciprofloxacin R* | 13 (46.4) | 4 (80) | 5 (71.4) | 9 (60) |
| ESBL* | 10 (35.7) | 4 (80) | 4 (2.3) | 7 (46.6) |
| P. aeruginosa | 71 (12) | 12 (11.7) | 23 (13.1) | 43 (11.4) |
| Ciprofloxacin R* | 42 (59.2) | 8 (66.7) | 15 (65.2) | 26 (60.5) |
| MDR* | 41 (57.7) | 8 (66.7) | 15 (65.2) | 25 (58.1) |
| S. maltophilia | 12 (2.0) | 6 (5.8) | 1 (0.6) | 9 (2.4) |
| Enterobacter spp | 8 (1.4) | 1 | 1 (0.6) | 4 (1.1) |
| Gram positive-bacteria | 323 (55) | 54 (52.4) | 102 (58.0) | 127 (60.5) |
| S. aureus | 19 (3.2) | 3 (2.9) | 6 (3.4) | 7 (1.9) |
| MRSA* | 4 (21) | 0 | 0 | 1(0.3) |
| CoNS | 211 (35.8) | 34 (33) | 76 (43.2) | 135(35.9) |
| Enterococcus spp | 64 (10.8) | 12 (11.7) | 9 (5.1) | 37(9.8) |
| E. faecalis* | 29 (45.3) | 2 (16.7) | 5 (55.6) | 11 (29.7) |
| E. faecium* | 33 (51.6) | 10 (83.3) | 4 (44.4) | 21 (56.8) |
| VRE* | 0 | 0 | 0 | 0 |
| S. pneumoniae | 6 (1) | 0 | 1 (0.6) | 0 |
| Group viridans streptococci | 18 (3) | 5 (4.9) | 7 (4) | 11(2.9) |
| L. monocytogenes | 6 (1) | 1 (1) | 1 (0.6) | 2(0.5) |
| Candida | 25 (4.2) | 13 (12.6) | 4 (2.3) | 19(5.1) |
| Polymicrobial | 57 (9.6) | 8 (7.8) | 13 (7.4) | 27(7.2) |
| MDR isolates | 110 (18.7) | 21 (20.4) | 31 (17.6) | 73 (19.5) |
*Percentage among their species.